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Methylation of lysine residues on histones critically contrib-utes to chromatin regulation1,2. This post-translational modification (PTM) provides a docking site for effector 
proteins, termed Kme readers, that recognize this PTM through 
an aromatic cage that accommodates the hydrophobic lysine side 
chain and engages the methylated amine through cation- , electro-
static and van der Waals interactions1. Selectivity between different 
methylation states (mono-, di- and trimethylation) is conferred pri-
marily by cage geometry and composition, while sequence specific-
ity is achieved through interactions with the amino acids flanking 
the modified lysine1,3.
Trimethyllysine 27 on histone 3 (H3K27me3) is a transcriptionally 
repressive signal that is installed by the methyltransferases EZH1 and 
EZH2 of Polycomb repressive complex 2 (PRC2). The other two core 
components of PRC2 are SUZ12 and the H3K27me3 reader EED4. 
In the ‘canonical’ Polycomb-signaling model, H3K27me3 is deposited 
by PRC2 and is then recognized by the chromodomain-containing 
Kme reader component of the multiprotein repressor complex 
PRC1. The PRC1 chromodomains (CBX2, CBX4, CBX6, CBX7 and 
CBX8) incorporate into PRC1 in a mutually exclusive manner5 and 
are thought to facilitate PRC1-mediated transcriptional repression 
by targeting the complex to H3K27me3, allowing the monoubiquit-
ination of Lys119 on H2A (H2AK119ub) by the E3 ubiquitin ligase 
subunits of PRC1, RING1A, RING1B and BMI6. H2AK119ub is in 
turn associated with chromatin compaction, DNA methylation and 
repression of the underlying genes7,8.
Notwithstanding this simplistic model of sequential PRC action, it 
has become clear that a large number of diverse PRC1 complexes exist. 
However, the role of this diversity in the context of specific gene reg-
ulation events or pathology is not understood. Further highlighting 
the complexity of PRC1, it was recently reported that EED, the 
H3K27me3 reader once believed to participate only in PRC2, is also 
a component of CBX-containing PRC1 complexes4, giving PRC1 
two potential Kme readers for the same mark. The variable CBX 
component is another point of diversity that potentially affects the 
genomic targeting of PRC1. However, the ability of CBX proteins 
to target PRC1 to overlapping regions of the genome9 suggests that 
these proteins may be partially functionally redundant. Therefore, 
modulation of chromatin regulation through PRC1 Kme reader 
antagonism may require ligands that target multiple CBX proteins.
Of the CBX chromodomains, CBX7 is the best studied and 
has been implicated as contributing to numerous cancer types9–19. 
Overexpression of CBX7 confers a proliferative advantage in pros-
tate, gastric, leukemia and lymphoma cell lines that can be inhibited 
through knockdown of CBX7 (refs. 9,10,17,18), while CBX2, CBX4 
and CBX8 have also been shown to enhance proliferation in various 
cancer types20–22. Interestingly, CBX7 also functions as a tumor sup-
pressor in lung, pancreatic, colon and thyroid tissues11,14–16. In addi-
tion to CBX7, other developmental Polycomb factors have similarly 
been shown to have contradictory functions in oncogenesis, for 
example the H3K27 demethylase JMJD3 (ref. 23).
Modulation of H3K27me3 signaling via small molecules has 
recently garnered much pharmaceutical interest. Inhibitors of the 
PRC2 methyltransferase EZH2 are effective at targeting aberrant 
H3K27me3 levels in lymphomas with activating mutations and are 
currently in clinical trials24. Inhibitors of the H3K27me3 demethylases 
JMJD3 and UTX also have growth-suppressive properties in acute 
lymphoblastic leukemia25 and robust antitumor activity in xenograft 
models of diffuse intrinsic pontine glioma26. Therefore, we hypoth-
esized that antagonism of the H3K27me3 reading function of PRC1, 
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We report the design and characterization of UNC3866, a potent antagonist of the methyllysine (Kme) reading function of the 
Polycomb CBX and CDY families of chromodomains. Polycomb CBX proteins regulate gene expression by targeting Polycomb 
repressive complex 1 (PRC1) to sites of H3K27me3 via their chromodomains. UNC3866 binds the chromodomains of CBX4 and 
CBX7 most potently, with a Kd of ~100 nM for each, and is 6- to 18-fold selective as compared to seven other CBX and CDY chromodo-
mains while being highly selective over >250 other protein targets. X-ray crystallography revealed that UNC3866’s interactions 
with the CBX chromodomains closely mimic those of the methylated H3 tail. UNC4195, a biotinylated derivative of UNC3866, 
was used to demonstrate that UNC3866 engages intact PRC1 and that EED incorporation into PRC1 is isoform dependent in PC3 
prostate cancer cells. Finally, UNC3866 inhibits PC3 cell proliferation, consistent with the known ability of CBX7 overexpression 
to confer a growth advantage, whereas UNC4219, a methylated negative control compound, has negligible effects. 
thought to occur immediately downstream of 
PRC2, may also have therapeutic potential. 
Although there have been other reports 
of ligands for PRC1 chromodomains27,28, 
no molecules have been reported that meet 
the stringent criteria29–31 for classification as a 
high-quality, cellularly active chemical probe. 
Chemical probes that inhibit the Kme3-
reading capacity of PRC1 will be valuable tools 
in explicating PRC1 biology, determining the 
therapeutic potential of CBX chromodomains, 
investigating potential pharmacologic synergy 
with inhibitors of EZH2 and of JMJD3 and 
UTX, and understanding the precise roles of 
CBX target genes in different cancer types. 
We report the design and characterization 
of UNC3866 as a potent and cellularly active 
antagonist of PRC1 chromodomains along 
with our initial investigation into the bio-
logical effects of antagonizing the H3K27me3 
reading function of CBX chromodomains in 
PC3 prostate cancer cells.
RESULTS
Molecular dynamics–based design of a 
CBX antagonist
Although the use of monospecific chemical 
probes is often desirable, probes with well-
characterized multitarget profiles are also of 
great utility and may, pragmatically, be the 
best tools achievable within highly homolo-
gous target families. For example, the initially 
reported bromodomain antagonists were 
not selective within the BET family, and yet 
their impact has been extraordinary32. The 
high degree of similarity between the CBX 
chromodomains of PRC1, particularly in the 
regions that interact with H3, suggests that 
any molecule that binds one of them is likely 
to have affinity for other Polycomb chromodo-
mains as well. With this in mind, we selected 
CBX7 as an initial target for ligand discovery 
because there is existing structural informa-
tion3, but with an understanding that quanti-
tative profiling versus other chromodomains would be required for 
full ligand characterization.
We first screened our epigenetic targeted library of small mol-
ecules designed largely for Kme reader domains and lysine methyl-
transferases using an established AlphaScreen competition assay33. 
Additionally, we screened a set of commercially available ligands 
known to interact with other quaternary ammonium–binding pro-
teins at concentrations up to 30 M (see Supplementary Results, 
Supplementary Fig. 1, for compound names and structures). 
This approach proved unsuccessful in identifying tractable hits 
capable of inhibiting the CBX7-H3 peptide interaction. Therefore, 
we turned to the existing structural information to guide our hit- 
discovery efforts. We compared the apo CBX7 NMR structure (PDB 
2K1B) with the H3K27me3-CBX7 NMR structure (PDB 2L12) and 
observed that the aromatic cage of CBX7 is unformed in the apo 
structure (Fig. 1a). The absence of a preformed aromatic cage makes 
the discovery of small-molecule Kme mimetics targeting this por-
tion of CBX7 a significant challenge. Histone peptide substrates, in 
contrast, engage CBX7 via an induced-fit, -sheet-like interaction 
that results in formation of the Kme-reading aromatic cage3.
Previous work using peptide arrays revealed that the overall CBX7 
consensus binding sequence is A(R/I/L/F/Y/V)Kme3(S/T)3. In fact, 
the sequence RGFALKme3STHG binds CBX7 with 22-fold greater 
affinity than the corresponding H3K27me3 peptide (Kd of 5 M 
and 110 M, respectively)3. Therefore, we initiated optimization 
of peptide-based ligands with the goal of enhancing potency while 
decreasing charge and polarity so as to improve cell permeability, a 
known challenge for peptides. We first replaced the arginine pre-
ceding the Kme3 with leucine to facilitate cell permeability, and an 
N-terminal benzoyl cap was chosen to further increase the lipophi-
licity and aid in purification. Our next priority was to address the
liabilities associated with Kme3: potential instability toward lysine
demethylases34 and limited passive membrane permeability due to
the permanent positive charge. A variety of peptides were prepared
and screened in which tertiary and secondary amines of varying
size, hydrophobicity and basicity were incorporated as replacements
for the quaternary amine. We were encouraged to find that replac-
ing the Kme3 with a diethyllysine residue in this context resulted
in a peptide, UNC3567 (1), that was approximately equipotent for
CBX7 to the original consensus peptide (Fig. 1b; Kd = 6.7  0.7 M
as determined by isothermal titration calorimetry). This develop-
ment represented encouraging progress toward our goal of cellu-
larly active PRC1 antagonists and justified further optimization of




























































































Figure 1 | Molecular dynamics–guided inhibitor design. (a) Comparison of the aromatic cage  
of CBX7 in the NMR structure of the apo (PDB 2K1B, dark gray) and H3K27me3-bound  
(PBD 2L1B, light gray, Kme3 shown in green) conformations of CBX7. (b) Structure of UNC3567.  
The Kd represents the average of three replicates  s.d. (c) Free energy plot from the CBX7-H3K9me3 
MDS studies. Arrows are drawn from potential energy wells to representative structures associated 
with that well. Frames “I” to “III” represent one possible dissociative path of H3 from CBX7, and the 
reverse sequence represents the corresponding associative path of CBX7 and H3. The “N terminus” 
label refers to the N terminus of CBX7. A, free energy; RMSD, root mean square deviation.
Because of the induced-fit recognition 
implied by prior structural studies3, we sought 
to better understand the critical CBX7-H3 
interactions that drive the conformational 
rearrangement of CBX7, whereby residues 
7–13 of CBX7 close around the histone and 
position Phe11 in close enough proximity to 
Trp32 and Trp35 to form the aromatic cage 
(Fig. 1a). We therefore turned to adaptively 
biased molecular dynamics simulations35 
(MDS) using the previously published NMR 
structure of H3K9me3 bound to CBX7 (PDB 
2L12). We computed possible histone exit 
paths from the CBX7–H3K9me3 structure, 
and the pathway shown in Figure 1c was 
favored when we considered a truncated form 
of H3K9me3 (residues 4–10), which is most 
analogous to UNC3567. Starting from the 
bound state as shown in Figure 1c, frame I, 
the N terminus of CBX7 opens by losing par-
tial contact with H3 (transition from frame 
I to frame II). Subsequently, the Kme3 loses 
contact with the aromatic cage (transition 
from frame II to III), leaving H3 engaged 
with CBX7 primarily through hydropho-
bic contacts made with V13, D50, R52 and 
L53 (frame III). Complete dissociation of 
H3 and CBX7 occurs following the loss of 
these contacts.
Association of CBX7 and H3 is simply 
the microscopic reversal of this exit path and 
is analogous to -hairpin folding between 
two antiparallel -strands. In this case, one 
-strand is formed by the histone and the other 
by residues 8–13 of CBX7 (Supplementary 
Fig. 2). Therefore, establishing the appropri-
ate contacts between the N-terminal portion 
of the H3 peptide (residue Q5; Fig. 1c, frame 
III) and CBX7 (namely residues V13, D50,
R52 and L53) during association is analogous 
to forming the critical -turn during hairpin 
folding. Once the turn is formed, backbone hydrogen bonds ‘zip’ 
the -hairpin into the fully folded state36,37. In the case of CBX7, in 
addition to causing the formation of an extensive hydrogen bond net-
work, this also orients Phe11 of CBX7 to contact Kme3 and facilitates 
formation of the aromatic cage. We used this pathway for H3 binding 
as a model for the association of CBX7 with UNC3567 and hypoth-
esized that optimizing the N-terminal interactions of UNC3567 with 
CBX7 would facilitate the necessary hydrogen bonding for closure of 
CBX7 around UNC3567, thereby increasing ligand affinity.
We synthesized a series of replacements for the N-terminal ben-
zoylglycine of UNC3567 that were less flexible and were predicted to 
interact favorably with V13, D50, R52 and L53 of CBX7. Structure-
activity relationship (SAR) studies ultimately led to the synthesis of 
UNC3866 (2) (Fig. 2a), which is, to our knowledge, the most potent 
ligand reported for CBX7, with a Kd of 97  2.4 nM (Fig. 2b; see 
Supplementary Table 1 for key SAR data that led to UNC3866). 
We also generated a negative control compound, UNC4219 (3), for 
use in cellular studies through methylation of the alanine residue at 
the N  position (Fig. 2a). This modification disrupts a key hydro-
gen bond, and, consistent with our simulations, UNC4219 shows no 
interaction with CBX7 at concentrations up to 100 M (Fig. 2b).
UNC3866 selectivity studies
Knowledge of the activity profile of a molecule is essential in order to 
associate its cellular effects with the modulation of a specific molecular 
target(s) of interest. Thus, the use and classification of a molecule 
as a chemical probe is dependent upon an in-depth understanding 
of its activity against a broad panel of potential molecular targets29. 
Accordingly, we evaluated the selectivity of UNC3866 against a wide 
range of both epigenetic and non-epigenetic targets. We first evalu-
ated its selectivity against a small set of Kme readers encompassing 
proteins from the MBT, PHD and Tudor families by AlphaScreen 
or ITC (Supplementary Table 2). UNC3866 is a potent antago-
nist of the CBX7-H3 interaction, as determined by AlphaScreen 
(IC50 = 66  1.2 nM), and is more than 100-fold selective for CBX7 
over the other nine members of this Kme reader panel.
To facilitate further selectivity studies, we generated a biotiny-
lated derivative of UNC3866, UNC4195 (4) (Fig. 2c), which retains 
high affinity for CBX7 (Kd = 220  22 nM). We used this derivative 
to evaluate binding to 96 purified chromatin-associated effector pro-
teins, including at least 19 known H3K9me3 or H3K27me3 binding 
proteins and 28 distinct chromodomains, spotted in duplicate 
onto a nitrocellulose-coated membrane (Fig. 2c, Supplementary 
Fig. 3a). Binding interactions were visualized with fluorescently 
tagged streptavidin, revealing that UNC4195 binds to two families 
of chromodomains. As expected, a positive binding interaction was 
observed with CBX7 and the other PRC1 orthologs, CBX2, CBX4, 
CBX6 and CBX8. We did not detect binding to CBX1, CBX3 or CBX5 
(also known as HP1 , HP1-  and HP1- , respectively), which are 
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Figure 2 | ITC studies of UNC3866 and UNC4219 with CBX7 and selectivity profiling of 
UNC3866. (a) Structures of UNC3866 (black) and the structurally related negative control 
compound, UNC4219 (blue). (b) Comparison of UNC3866 (Kd = 97  2.4 nM, average of three 
replicates  s.d.) and UNC4219 (no interaction up to 100 M) binding to CBX7 as measured by 
ITC. Top graph shows raw titration heat values ( cal/s) plotted against time after the integration 
baseline has been subtracted.  Bottom graph shows normalized integration heat values  
(kcal mol-1) of injectant plotted against molar ratio. (c) Structure of UNC4195, a biotinylated 
derivative of UNC3866. (d) UNC4195 selectively interacts with two subfamilies of chromodomains 
on a microarray containing 96 epigenetic reader proteins across multiple domain types.
members of the CDY family of chromodomains: CDY1, CDYL1b 
and CDYL2. We expressed and purified all proteins that showed 
positive binding to UNC4195 on the array and subsequently quanti-
fied the affinity for UNC3866 by ITC (Table 1 and Supplementary 
Fig. 3b). In agreement with the microarray data, we detected bind-
ing to each of these chromodomains. We also found that the affinity 
of UNC3866 for CBX2, CBX4, CBX6 and CBX8 is surprisingly well 
correlated with the percent sequence identity of each chromodo-
main relative to that of CBX7 (Supplementary Fig. 3c). UNC3866 
is equipotent for CBX4, which is most similar to CBX7, whereas 
it is 18-, 6- and 12-fold selective for CBX4 and CBX7 over CBX2, 
CBX6 and CBX8, respectively. Additionally, UNC3866 is 65-fold 
selective for CBX4 and CBX7 over CDY1 and 9-fold selective for 
CBX4 and CBX7 over CDYL1b and CDYL2. Although some work 
has been done to explore the biochemistry of CDY proteins38, their 
biological function is less well characterized than that of Polycomb 
CBX proteins, which makes assessing the potential consequences of 
antagonizing these proteins in a cellular context challenging. This is 
a ‘known unknown’ in the use of UNC3866.
UNC3866 was also evaluated against a panel of 48 bromodo-
mains, 33 protein methyltransferases and 7 lysine demethylases 
and found to be inactive in each case (Supplementary Fig. 4 and 
Supplementary Tables 3 and 4). UNC3866 was tested against a gen-
eral pharmacology panel (Cerep) consisting of 49 G protein-coupled 
receptors (GPCRs), 5 ion channels and 3 transporter proteins 
(Supplementary Table 5) as well as against the National Institute 
of Mental Health’s Psychoactive Drug Screening Program (NIMH 
PDSP) panel, which includes 22 additional GPCRs. Follow-up func-
tional assays39,40 for targets displaying >50% inhibition of control 
radioligand binding at 10 M UNC3866 were also performed with 
both UNC3866 and UNC4219 (negative control) (Supplementary 
Figs. 5–8). Both UNC3866 and UNC4219 showed nearly identical 
profiles in these follow-up assays, with both compounds having very 
weak antagonism for the NK2 and V1a receptors (Supplementary 
Figs. 6 and 8a). The similar profiles of 
UNC3866 and UNC4219 indicate that 
UNC4219 will be a valuable negative control 
in determining the biological consequences 
specific to chromodomain antagonism.
UNC3866 cocrystallization studies
We additionally solved an X-ray cocrystal 
structure of UNC3866 bound to CBX7 (PDB 
5EPJ) at a resolution of 1.6 Å to improve our 
understanding of its binding interactions. Each 
backbone amide of UNC3866 participates in 
at least one hydrogen bond with the backbone 
of CBX7 (Fig. 3a,b), while the N-terminal 
tert-butylbenzoyl cap of UNC3866 primarily 
contacts the side chains of D50, R52 and L53 
(Fig. 3c). The guanidinium moiety of R52 forms a salt bridge with 
D50, and this rigidified R52 side chain forms a hydrophobic groove 
with L53 within which the tert-butylphenyl group of UNC3866 
is embedded. On the basis of our MDS studies, we suspect that 
the 70-fold affinity increase observed upon substitution of the 
benzoylglycyl cap of UNC3567 for the tert-butylbenzoyl cap of 
UNC3866 is the result of an improvement in the ability of this 
moiety to nucleate closure of CBX7 around the molecule through 
interactions with D50, R52 and L53.
Additionally, we solved X-ray crystal structures of UNC3866 
bound to CBX2 (PDB 5EPK), CBX4 (PDB 5EPL) and CBX8 (PDB 
code 5EQ0) in order to better understand the selectivity profile 
of UNC3866 (Fig. 3d and Supplementary Fig. 9). Alignment of 
these structures clearly illustrates that UNC3866 binds in a similar 
fashion to each chromodomain (Supplementary Fig. 9a). A closer 
inspection of the binding pocket for the alanine of UNC3866 in 
each protein revealed that the improved potency of UNC3866 for 
CBX4 and CBX7 over CBX2 and CBX8 might be the result of a 
subtle, yet significant, difference in this pocket. The alanine pocket 
in CBX2 and CBX8 consists of a valine, leucine and alanine, whose 
side chains form a relatively open hydrophobic pocket that binds 
the UNC3866 alanine methyl group. In contrast, in CBX4 and 
CBX7 this pocket is made up of two valines and a leucine (Fig. 3d, 
Supplementary Fig. 9b–f), which mold more tightly to the alanine, 
enhancing the van der Waals interactions with UNC3866. This sin-
gle residue is likely to be the predominant factor that determines 
the higher affinity of UNC3866 for CBX4 and CBX7, as there are 
no other significant variations within the amino acids that interact 
directly with UNC3866.
In the absence of cocrystal structures, it is more challenging 
to explain the selectivity of UNC3866 for CBX4 and CBX7 over 
the CDY proteins. Alignment of the sequences (Supplementary 
Fig. 9f) of the CBX and CDY proteins that bind UNC4195 on the 
microarray (Fig. 3a) indicates that the key motif in the CBX fam-
ily that engages the tert-butyl of UNC3866 (D-X-R) is replaced by 
an  (N/H)-C-E motif in the CDY proteins. Given the demonstrated 
importance of this interaction in the binding of UNC3866 to CBX7, 
this sequence variation may contribute to the modest selectivity of 
UNC3866 for CBX4 and CBX7. Further structural and in-depth 
SAR studies are needed to obtain a more complete understanding 
to aid in the design of selective ligands.
We were also interested in the interactions between the Polycomb 
CBX chromodomains and the diethyllysine of UNC3866 revealed by 
our structures. Whereas the H3K27me3 side-chain has been mod-
eled as adopting a fully extended, all-anti conformation3, the lysine 
side chain of UNC3866, when bound to CBX proteins in our crystal 
structures, is modeled as adopting a gauche conformation about 
the C -C  bond in Figure 3a. Although the corresponding electron 
density is comparatively weak for CBX7 (Supplementary Fig. 10a), 
we model the side chain in the gauche conformation based on the 
Table 1 | Quantitative analysis of UNC3866 binding to CBX and 
CDY chromodomains by ITC
Chromodomain UNC3866 Kd ( M)
CBX2 1.8  0.21
CBX4 0.094  0.017
CBX6 0.610  0.0078
CBX7 0.097  0.0024
CBX8 1.2  0.021
CDY1 6.3  0.92
CDYL1b 0.91  0.076
CDYL2 0.85  0.076










Figure 3 | Structural studies of UNC3866 with CBX7 and CBX8. (a) Interaction of CBX7  
(PDB 5EPJ; surface shown) with the C-terminal portion of UNC3866 (green; serine methyl ester 
only partially resolved by electron density). (b) Interaction of CBX7 with the N-terminal portion of 
UNC3866. (c) Interactions of the tert-butylbenzoyl cap of UNC3866 with the hydrophobic groove 
formed by CBX7 residues D50, R52 and L53. (d) Comparison of the UNC3866 alanine-binding 
pocket in CBX7 and CBX8 (PDB 5EQ0) (top and bottom panels, respectively).
higher-resolution CBX8-UNC3866 cocrystal structure (1.2 Å as 
compared to 1.6 Å for the CBX7-UNC3866 structure). Although 
the electron density of the CBX8-UNC3866 structure more strongly 
supports the gauche conformation of this side chain in the bound 
state (Supplementary Fig. 10b), the ambiguity in the position of 
these atoms may reflect that the side chain in UNC3866 remains 
somewhat flexible when bound to CBX7. Further, this apparent 
flexibility in the bound state may explain the ability of CBX7 and 
the other Polycomb chromodomains to accommodate the diethyl 
functional group, which is more sterically demanding than the 
endogenous Kme3 recognized by these domains.
UNC4195 engages ‘canonical’ PRC1
Chemiprecipitation experiments in PC3 prostate cancer cell lysates 
were performed with UNC4195 in order to investigate its utility as 
a CBX pulldown reagent. PC3 cells were chosen for their relatively 
high abundance of each CBX Polycomb protein and their prior uti-
lization to study CBX7 function10. Upon chemiprecipitation with 
UNC4195, we probed for the presence of CBX2, CBX4, CBX6, 
CBX7 and CBX8. We detected pulldown of CBX4, CBX7 and CBX8, 
which was inhibited by the presence of excess UNC3866 in the lysate 
(Fig. 4a), confirming that successful pulldown is dependent on the 
specific binding of the chromodomains to UNC4195. We failed to 
pull down CBX2 and CBX6 in these experiments, suggesting that, 
in contrast to CBX4, CBX7 and CBX8, CBX2 and CBX6 partici-
pate in PRC1 complexes in such a way that their chromodomains 
become inaccessible to pulldown with UNC4195. This is supported 
by the fact that the purified, isolated chromodomains of CBX2 and 
CBX6 interact with UNC4195 on the microarrays (Fig. 2c). We also 
investigated the ability of UNC4195 to chemiprecipitate PRC1 as an 
intact complex by probing for representative proteins of the remain-
ing three ‘canonical’ PRC1 subunits (Fig. 4b). We detected RING1b, 
BMI-1 and HPH2, indicating that UNC4195, and by extension 
UNC3866, engages ‘canonical’ PRC1 without disrupting the 
complex’s core composition.
Isoform-specific incorporation of EED into PRC1
The recent finding that EED can participate in CBX-containing 
PRC1 complexes intrigued us4; therefore, we investigated the ability 
of UNC4195 to pull down EED in PC3 cells. Three of the four mam-
malian isoforms of EED (EED1, EED3 and EED4)41 were detected in 
the PC3 lysate input; however, UNC4195 pulled down only EED3 and 
EED4, both of which could be competed away through the addition 
of UNC3866 to the lysate (Fig. 4b). Additionally, because EED binds 
H3K27me3 via its WD40 Kme reading domain, we confirmed that 
UNC3866 does not bind directly to EED (Supplementary Fig. 11), 
indicating that the pulldown is mediated through incorporation 
of EED into PRC1. We next investigated the presence of EED iso-
forms in PRC2 using the EZH1 and EZH2 biotinylated pulldown 
reagent UNC2399 (ref. 24). Interestingly, we detected only EED4 
(Supplementary Fig. 12). It has been shown that the incorporation 
of different isoforms of EED into PRC2 can dictate the in vitro  
histone substrate of PRC2 (ref. 42), and hence our discovery that 
EED incorporates into PRC1 in an isoform-dependent fashion pro-
vides the basis for future work to examine the effects of these iso-
forms on PRC1 function. Furthermore, the absence of EED1 in both 
PRC1 and PRC2 raises questions about the binding partners and 
function of this isoform in PC3 cells.
UNC3866 antagonizes PRC1 chromodomains in cells
We next assessed the utility of UNC3866 in a cellular context. As 
peptide inhibitors often have poor cellular activity, we evaluated the 
permeability of UNC3866 using a Caco-2 assay and found it to be 
low (Supplementary Fig. 13), indicating a need for relatively high 
compound concentrations for cellular studies relative to the in vitro 
Kd. Additionally, we noted the potential for UNC3866 to serve as a 
prodrug if the C-terminal methyl ester is susceptible to hydrolysis 
by intracellular esterases; therefore, we confirmed through a com-
bination of pulldown and ITC experiments that the corresponding 
C-terminal acid, UNC4007 (5), is still capable of engaging PRC1
chromodomains (Supplementary Fig. 14 and 20). Next, we quanti-
fied the intracellular concentration of both UNC3866 and UNC4007
by LC-MS/MS (Supplementary Table 6). Owing to the low Caco-2
permeability, we incubated PC3 cells with 30 M UNC3866 to
ensure sufficient accumulation of intracellular UNC3866. Treatment
for 24 h resulted in an intracellular concentration of 1.4  0.3 M,
indicating that the intracellular concentration of UNC3866 is ~5%
of the extracellular concentration. The UNC3866 intracellular
concentration was approximately seven-fold higher than the intra-
cellular concentration of UNC4007, indicating that hydrolysis of
UNC3866 is limited under these conditions. Overall, UNC3866 is
sufficiently cell permeable and stable that it is possible to evaluate
its ability to engage and antagonize the functions of its chromodo-
main targets in cells.
The nonenzymatic nature of chromodomains makes dem-
onstrating cellular engagement of these proteins challenging. 
Although PRC1 has E3 ligase activity, the presence of noncanoni-
cal PRC1 complexes that do not contain CBX proteins6 makes 
monoubiquitination of H2AK119 an unreliable readout. Further, 
neither mutation nor deletion of the chromodomains of CBX 
proteins has significant effects on the cellular mobility of these 
proteins as determined by fluorescence recovery after photo-
bleaching (FRAP) experiments43, ruling out this technique, which 
has been previously applied to chromatin readers32,33. We failed to 
detect thermostabilization of CBX7 by UNC3866 in cell lysates 
(Supplementary Fig. 15), likely because the chromodomain com-
prises a relatively small portion (~25%) of the full-length protein, 
which precludes evaluation of cellular target engagement via the 
cellular thermal shift assay (CETSA)44. Therefore, we hypoth-
esized that competition-based chemiprecipitation experiments 
could be used to demonstrate cellular target engagement, with 
the expectation that pretreatment with UNC3866 would block 
chemiprecipitation. Whole PC3 cells were incubated with varying 
concentrations of UNC3866 for 24 h, after which excess medium 
and compound were removed and the cells were washed, harvested 
with trypsin and lysed. Encouragingly, CBX7 chemiprecipitation 
with UNC4195 was completely inhibited in lysates from cells pre-
treated with 30 M UNC3866 (intracellular concentration = 1.4 
0.3 M, Fig. 4c), indicating that UNC3866 effectively engages















































Figure 4 | UNC4195 pulldown studies in PC3 cells. (a) UNC4195 
selectively chemiprecipitates CBX4, CBX7 and CBX8 from PC3 cell 
lysates and chemiprecipitates additional PRC1 components. (b) UNC4195 
chemiprecipitates EED3 and EED4 from PC3 cell lysates. (c) Incubation 
of intact PC3 cells with UNC3866 for 24 h inhibits pulldown of CBX7 with 
UNC4195. n = 3 for all samples in a–c. Full-sized western blots are provided 
in Supplementary Figure 19.
We next focused on establishing a bio-
logical consequence of treating cells with 
UNC3866. The high levels of CBX proteins 
in PC3 cells, coupled with the demonstrated 
ability of CBX7 overexpression to confer a 
growth advantage in these cells10,45, encour-
aged us to investigate the effects of UNC3866 
on PC3 cell proliferation. As a prelude to 
these studies, we confirmed that treatment 
with UNC3866 up to 100 M did not induce 
any toxic effects, as assessed by CellTiter-Glo 
in PC3 and HEK293T cells (Supplementary 
Fig. 16). Similarly, UNC4219 had no observ-
able toxicity within the same concentration 
range. HEK293T cells were used to evaluate 
UNC3866 toxicity in a noncancerous cell line. 
To assess effects on proliferation, PC3 cells 
were treated with UNC3866 and the negative 
control, UNC4219, at 30 M, as this concen-
tration was shown to effectively engage CBX7 
in cells (Fig. 4c). Consistent with the known 
ability of CBX7 to enhance proliferative capac-
ity in PC3 cells14,45, we observed a dramatic 
decrease in cell proliferation upon UNC3866 
treatment, resulting in almost no change in 
cell count after 3 and 6 d, while cells treated 
with UNC4219 or DMSO exhibited exponen-
tial cell growth (Fig. 5a). Further, we observed 
that cells resumed proliferating when washed 
and not replenished with UNC3866 after 3 d 
(Fig. 5a, dotted line), indicating that the com-
pound’s effects are at least partially revers-
ible. We next examined dose dependency for 
UNC3866 and UNC4219, and we observed a 
significant reduction in PC3 cell count only 
for UNC3866-treated cells, resulting in an 
EC50 of 7.6  2.5 M (Fig. 5b). The intracel-
lular concentration of UNC3866 at its EC50 in 
PC3 cells is therefore estimated to be 340 nM, 
which is adequate to fully engage CBX4 and CBX7 given the mea-
sured ~100 nM Kd values against these targets (Fig. 3b). Although 
some contribution to this antiproliferative phenotype from other 
chromodomains bound by UNC3866 cannot be ruled out, the con-
cordance of this result with previously published data from CBX7 
genetic manipulation studies is striking17,18.
We also observed that PC3 cells treated with UNC3866 
exhibited an enlarged and flattened morphology (Fig. 5c), sug-
gesting that they had become senescent46. We checked for the 
presence of senescence-associated -galactosidase (SA- -gal) and 
observed a dramatic increase in the number of cells positive for 
SA- -gal following treatment with 30 M UNC3866 (Fig. 5d). 
This was an intriguing observation because CBX7 was originally 
identified in a genetic screen for genes capable of bypassing rep-
licative senescence in human prostate epithelial cells (HPrEC)18. 
Furthermore, the same study observed that CBX7 knockdown is 
capable of inducing senescence.
Although it has been suggested that CBX7 controls cellular pro-
liferation through regulation of the Ink4a/ARF (CDKN2A) locus18, 
its actual role in regulating this locus is controversial9,11,18. For 
example, CBX7 has been shown to enhance proliferative capacity 
without negatively regulating Ink4a/ARF9, and negative regulation 
of this locus does not necessarily enhance proliferative capacity14. 
Nonetheless, we analyzed the expression of Ink4a/ARF in response 
to knockdown of CBX7 by shRNA (>60% mRNA reduction) in PC3 
cells and did not observe a statistically significant change in expres-
sion. Further, evaluation of the effects of UNC3866 on expression of 
this locus showed no change at 30 M, ruling out Ink4a/ARF regu-
lation in the antiproliferative effects of UNC3866 (Supplementary 
Fig. 17). This was not entirely surprising as there is considerable 
evidence indicating that this locus is deeply repressed in PC3 
cells through DNA hypermethylation47–50. Further, methylation of 
Ink4a/ARF is unaffected by both DNMT knockdown and inhibition 
with 5-AzaC, suggesting that this gene may be irreversibly repressed 
in PC3 cells47–49.
Finally, we evaluated the stability of UNC3866 following intrap-
eritoneal injection (10 mg/kg) in male Swiss albino mice and found 
that UNC3866 is the predominant species in plasma at all time 
points tested, relative to UNC4007 (Supplementary Tables 7–9 
and Supplementary Fig. 18), and shows 25% bioavailability and 
moderate clearance. Although these pharmacokinetic results are 
promising for a peptidic compound, the use of UNC3866 in vivo 
may be limited by the high circulating levels required for intra-
cellular target engagement because of its poor cell permeability. 
The potential utility of UNC3866 at higher doses for in vivo experi-
ments is currently under investigation.
DISCUSSION
Our investigations into the molecular dynamics of H3 recognition 
by CBX7 enabled the design of UNC3866, the most potent CBX7 
antagonist reported to date27,28. UNC3866 is an equipotent nano-
molar inhibitor of CBX4 and CBX7 Kme recognition in vitro, with 
a thoroughly characterized selectivity profile. Further, through 
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Figure 5 | Cellular effects of UNC3866. (a) Treatment of PC3 cells with 30 M UNC3866 
inhibits cell proliferation. UNC4219 treatment has no effect on PC3 cell proliferation. For washout 
experiments (dotted line), UNC3866 was not replenished at day 3. Error bars represent the s.d. 
of each data point (n = 3, single biological replicate with three technical replicates). The data are 
representative of at least four biological replicates with varying plating densities. (b) UNC3866 
inhibits PC3 cell proliferation in a dose-dependent manner after exposure for 6 d (n = 8, two 
biological replicates with three technical replicates and one biological replicate with two technical 
replicates). The EC50 is reported as the 95% confidence interval. UNC4219 was used to control for 
off-target effects, which were not evident at concentrations below 100 M. The EC50 for UNC4219 
is >76 M, which is the lower bound of the 95% confidence interval (n = 6, three biological 
replicates with two technical replicates each). Error bars represent the s.e.m. of each data point. 
(c,d) UNC3866 induces a senescent-like morphology in PC3 cells (c) and expression of SA- -gal 
(d). Arrows indicate examples of positive SA- -gal expression. Cell morphology was assessed 
using phase-contrast microscopy (40×). SA- -gal expression was assessed using bright-field 
microscopy (40×). The images are representative of three biological replicates, and the black scale 
bars are equal to 60 m.
the context of intact, ‘canonical’ PRC1. Finally, UNC3866 exhibits 
micromolar cellular potency in competition pulldown and cellular 
proliferation assays with no associated toxicity. The replacement of 
the quaternary amine of the native peptide ligand with an unnatural 
tertiary amine mimetic was a key achievement in the development 
of a cellularly active ligand, and, more broadly, this signifies that a 
quaternary amine is not required for inhibition of Kme3 readers.
Knowledge of the activity profile of a molecule is essential in 
order to associate its cellular effects with modulation of a specific 
molecular target(s) of interest. Although UNC3866 is most potent 
for CBX4 and CBX7, it possesses affinity for other Polycomb CBX 
proteins and the CDY family of chromodomains. Its use as a chemi-
cal probe will require consideration of these activities and evalua-
tion of dose dependency to assess possible affects from these other 
targets. This is not unusual for first-in-class chemical probes: for 
example, the initially reported bromodomain antagonists were not 
selective within the BET family and yet their utility is well estab-
lished32. The thorough characterization of the in vitro selectivity of 
UNC3866 versus >250 proteins, the demonstrated cellular target 
engagement of UNC3866, and the use of UNC4219 as a negative 
control validate UNC3866 as the first high-quality chemical probe 
for both the Polycomb CBX family of Kme readers and, to our 
knowledge, any Kme3 reader.
Our work toward the development of chemical tools for 
Polycomb CBX Kme readers has revealed that EED is incorporated 
into PRC1 and PRC2 in an isoform-dependent manner in PC3 cells, 
providing the basis for future investigation into the biochemical 
role of the different EED isoforms in Polycomb-mediated signaling.  
The ability of UNC3866 to inhibit PC3 cell proliferation supports 
further investigation of the use of PRC1 chromodomain antagonists 
as therapeutics in oncology, alone or in combination with EZH2 
inhibitors. In addition to their role in different cancers, PRC1 chro-
modomains play a pivotal role in regulating cellular differentiation9, 
and UNC3866 and its related derivatives provide a new set of tools 
that will assist in further probing the role of PRC1 chromodomains 
in cell fate determination and, more generally, in understanding 
Polycomb signaling. 
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METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Protein Data Bank: CBX2 with UNC3866 bound, 
5EPK; CBX4 with UNC3866 bound, 5EPL; CBX7 with UNC3866 
bound, 5EPJ; CBX8 with UNC3866 bound, 5EQ0.
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ONLINE METHODS
Experimental methods. Adaptively biased molecular dynamics simulations. 
Adaptive biasing potential35 was implemented in GROMACS 4.5.5 (ref. 51). 
The bias parameters were b = 0.8, c = 0.0005/ t, where t = 2 fs is the molecu-
lar dynamics time step. The Gaussian width was 1/4 Å. This choice of bias 
parameters floods stable states extremely slowly, to minimize adaptation of the 
bias near transition states. Thus, one may argue for approximate state-to-state 
dynamics as has recently been done for metadynamics52 following the princi-
ples of hyperdynamics53. Using the first frame of the CBX7+H3K9me3 NMR 
structure, two collective variables were defined: r.m.s. deviation of clasp, and 
r.m.s. deviation of peptide. We used the Kabsch algorithm to align the reference  
and trajectory during the simulation. All simulations were performed in 
a cubic box with a minimum of 12 Å between the protein or peptide and  
the nearest cube face, resulting in 23,710 atoms after adding water and salt. 
System construction included 5 ns of isothermal–isobaric equilibration at  
1 bar. Production simulations were carried out in the canonical ensemble 
with stochastic velocity rescaling54. Van der Waals and direct electrostatic 
interactions used a 10 Å cutoff. Long-range electrostatics were treated with 
the particle mesh Ewald approach with a grid spacing of 1.6 Å. The neighbor 
list was updated every five steps. We ran five 128 ns simulations to get some 
intuition that could inform ligand design. All images from the simulations 
were rendered using the PyMOL Molecular Graphics System, Version 1.7.4 
Schrödinger, LLC.
ITC experiments. All ITC measurements were recorded at 25 °C with an 
AutoITC200 microcalorimeter (MicroCal Inc., MA). All protein and com-
pound stock samples were in the target buffer (25 mM Tris-HCl, pH 8, 150 mM  
NaCl, and 2 mM -mercaptoethanol) and then diluted in the same buffer to 
achieve the desired concentrations: 50 M protein and 0.5 mM compound. 
The concentration of the protein stock solution was established using the 
Edelhoch method, whereas compound stock solutions were prepared based 
on mass. A typical experiment included a single 0.2 l compound injection 
into a 200 l cell filled with protein, followed by 26 subsequent 1.5 l injec-
tions of compound. Injections were performed with a spacing of 180 s and a 
reference power of 8 cal/s. Control experiments were performed titrating  
each compound into buffer under identical conditions to determine the 
heat signals, if any, that arise from diluting the compound. If applicable, the 
heats of dilution generated were then subtracted from the protein-compound  
binding curves. The initial data point was routinely deleted. The titration 
data was analyzed using Origin Software (MicroCal Inc., USA) by nonlinear  
least-squares, fitting the heats of binding as a function of the compound: 
protein ratio to a one site binding model.
Kme reader AlphaScreen assays. The AlphaScreen assay (Perkin Elmer) 
was generally performed as previously described55. In brief, compound plates  
(1 l at 10 mM highest concentration; 3-fold, 10-point dilutions in DMSO) 
were diluted in 1× assay buffer (20 mM TRIS pH 8.0, 25 mM NaCl, 2 mM DTT 
and 0.05% Tween-20) to 1 mM using a Multimek robotic pipettor (Nanoscreen) 
and 1 l was spotted into the wells of 384-well low-volume Proxiplates (Perkin 
Elmer). To these plates 9 l of protein-peptide mix (Supplementary Table 10)  
in 1× assay buffer was added by Multidrop (Thermo) to bring the final com-
pound concentration to 100 M and incubated for 30 min at room temperature. 
Next, 2 l of a 1:1 mixture of streptavidin-conjugate donor and nickel-chelate 
or -GST acceptor beads (45 g/ml in 1× assay buffer) were added and the 
plates were allowed to incubate for an additional 30 min in the dark at room 
temperature. After incubation, the plates were read on an EnVision multi-
label reader equipped with an HTS AlphaScreen laser (Perkin Elmer). The 
expression and purification of the constructs used in this assay was described 
previously56.
Methyltransferase selectivity assays. The effect of UNC3866 on the methyl-
transferase activity of G9a, EHMT1, SUV39H1, SUV39H2, SETDB1, SETD8, 
SUV420H1, SUV420H2, SETD7, MLL1 trimeric complex, MLL3 tetra-
meric complex, EZH2 trimeric complex, PRMT1, PRMT3, PRMT5-MEP50 
complex, PRMT6, PRMT7, PRMT8, PRDM9, SETD2, SMYD2, SMYD3, 
BCDIN3D and DNMT1 was assessed by monitoring the incorporation of 
tritium-labeled methyl group to lysine or arginine residues of peptide sub-
strates using Scintillation Proximity Assay (SPA) as previously described57. 
Assays were performed in a 20 l reaction mixture containing 3H-SAM  
(Cat. # NET155V250UC; Perkin Elmer; www.perkinelmer.com) at substrate 
concentrations close to the Km values for each enzyme. Three concentrations 
(1 M, 10 M, and 50 M) of UNC3866 were used in all selectivity assays. 
To stop the enzymatic reactions, 7.5 M guanidine hydrochloride was added, 
followed by 180 l of buffer (20 mM Tris, pH 8.0). The reactions were mixed 
and then transferred to a 96-well FlashPlate (Cat. # SMP103; Perkin Elmer; 
http://www.perkinelmer.com). The reaction mixtures in Flash plates were 
incubated for 1 h and the CPM were measured using a TopCount plate reader 
(Perkin Elmer). The CPM counts in the absence of compound for each data set 
were defined as 100% activity. In the absence of the enzyme, the CPM counts 
in each data set were defined as background (0%).
For DOT1L, NSD1, NSD2, NSD3, ASH1L, METTL21A, METTL21D, 
DNMT3A/3L, and DNMT3B/3L, a filter-based assay was used. In this assay, 20 l 
of reaction mixtures were incubated at 22 °C for 1 h, 100 l of 10% trichloroace-
tic acid (TCA) was added, and the samples were mixed and transferred to filter-
plates (Millipore; cat.# MSFBN6B10; http://www.millipore.com). Plates were 
centrifuged at 2000 rpm (Allegra X-15R - Beckman Coulter, Inc.) for 2 min, 
followed by two additional 10% TCA washes, one ethanol wash (180 l), 
and centrifugation. Plates were dried and 100 l of MicroO (MicroScint-O; 
Cat. # 6013611, Perkin Elmer; www.perkinelmer.com) was added to each well, 
centrifuged and removed. Another 70 l of MicroO was added and the CPM 
was measured using a TopCount plate reader.
Bromodomain selectivity assays. Thermal melting experiments were carried 
out using an Mx3005p Real Time PCR machine (Stratagene). Proteins were 
buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well plate 
at a final concentration of 2 M in 20 L volume. Compounds were added 
at a final concentration of 25 M. SYPRO Orange (Molecular Probes) was 
added as a fluorescence probe at a dilution of 1:1,000. Excitation and emission 
filters for the SYPRO-Orange dye were set to 465 and 590 nm, respectively. 
The temperature was raised with a step of 3 °C per minute from 25 °C to 96 °C 
and fluorescence readings were taken at each interval.
Demethylase AlphaScreen assays. The demethylase AlphaScreen assay was 
performed in 384-well plate format using white proxiplates (Perkin Elmer) and 
compound transfers (100 nl) were performed using an ECHO 550 Acoustic 
Dispenser (Labcyte). All subsequent steps were carried out in assay buffer 
(50 mM HEPES pH 7.5, 0.1% (w/v) Bovine Serum Albumin and 0.01% (v/v) 
Tween-20). In brief, 5 ml of assay buffer containing demethylase enzyme at 2× 
final assay concentration (see Supplementary Table 11–13 for assay specif-
ics) was pre-incubated for 15 min with dilutions of compound. The enzyme 
reaction was initiated by addition of substrate (5 ml) consisting of l-ascorbic 
acid (100 mM), 2-oxoglutarate (2× final assay concentration), ferrous ammo-
nium sulfate (2× final assay concentration) and histone H3 substrate pep-
tide (2× final assay concentration) and the enzyme reaction was allowed to 
proceed for the required time. The final assay DMSO concentration was 1%. 
The enzyme reaction was stopped by addition of 5 ml assay buffer containing 
EDTA (30 mM) and NaCl (800 mM). Streptavidin Donor beads (0.08 mg/ml) 
and Protein-A conjugated acceptor beads (0.08 mg/ml) were pre-incubated 
for 1 h with anti-methyl mark antibody (4× final assay concentration) and the 
presence of histone H3 product methyl mark was detected by addition of the 
pre-incubated AlphaScreen beads (5 ml). Detection was allowed to proceed for 
2 h at room temperature and the assay plates were read in a BMG Pherastar FS 
plate reader (Excitation 680 nM / Emission 570 nM). Data were normalized to 
the no enzyme control and the IC50 determined from the nonlinear regression 
curve fit using GraphPad Prism 5.
NIMH PDSP functional assays. The NK1 and NK2 receptors; -, -, and 
-opioid receptors; and V1A, V1B and V2 receptor functional assays were 
performed according to the NIMH PDSP Assay Protocol Book Version II 
found at https://pdspdb.unc.edu/pdspWeb/?site=binding.
Cell culture and lysis. PC3 cells were obtained from ATCC (CRL-1435) 
through the UNC Lineberger Tissue Culture Facility. Cells were cultured 
using GIBCO DMEM/F12 (Ham) supplemented with l-glutamine and 15 mM 
HEPES. Cells were trypsinized using 0.25% trypsin. Lysis was performed using 
Cytobuster protein extraction reagent supplemented with protease inhibitors 
and Benzonase (used at 25 U/ml). Samples were incubated at 37 °C for 10 min, 
followed by incubation at RT on a rotator for 20 min. The samples were spun 
down and the supernatant collected and transferred to a clean Eppendorf tube. 
Protein concentrations were quantified using the Bradford protein assay.
Pulldown studies. Cells were cultured on a T175 tissue culture flask until 
reaching ~80–90% confluency. Following trypsinization, the pellet was washed 
twice with PBS and lysed with 500 l of lysis buffer. When applicable, vehicle 
control or 100 M UNC3866 was added to an aliquot of 1,000 g of total protein 
and diluted to 500 l with 20 mM Tris (pH 8)/150 mM NaCl/0.1% Tween-20 
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(TBST). Pulldown reagents were bound to Streptavidin M-270 Dynabeads by 
rotating 30 l of beads with a 20-fold excess of pulldown reagent for 30 min at 
room temperature in. Unbound pulldown reagent was then removed and the 
beads were washed 3× with 200 l of TBST. The lysate was then transferred 
to an Eppendorf tube containing 30 l of Streptavidin M-270 Dynabeads that 
had been pre-bound to UNC4195 or 2399. The mixture was rotated overnight 
at 4 °C. The following morning, the depleted lysate was removed and the beads 
were washed 3× with 300–500 l of TBST. The beads were re-suspended with 
30 l of 1× Laemmli sample buffer and heated at 95 °C for 3 min. Fifteen 
microliters of the sample was then loaded into a gel and analyzed via western 
blotting using the appropriate primary antibody (Supplementary Table 14) 
and detected using a LI-COR Odyssey instrument and the appropriate fluo-
rescent secondary antibodies (diluted 1:10,000 in PBST). One percent of input 
was used for western blotting of all proteins except CBX8 and HPH2. For both 
of these proteins, 3% of sample input was used.
Cell proliferation assay. PC3 cells were seeded at 200 cells/well into 24-well 
plates (Costar #3524). Cells were allowed to adhere overnight. The media 
(DMEM supplemented with 10% FBS) was then exchanged with fresh 
media containing DMSO, UNC3866 or UNC4219. On day 3, the media were 
exchanged with fresh media containing DMSO, UNC3866 or UNC4219. For 
dose-response studies, the EC50 was derived from a six-point titration ranging 
from 100 M to 0.4 M of UNC3866 or UNC4219. At day 0, 3 or 6, cells were 
fixed with ice-cold methanol for 30 s. and rehydrated with PBS. Nuclei of the 
cells were stained with DAPI (0.05 g/ml) and numerated using High Content 
Microscopy (Array Scan High Content Analysis, Thermo Fisher #NX10002L). 
For dose-response studies, the cell count of UNC3866- or UNC4219-treated 
cells was normalized to the average cell count of DMSO-treated cells. The EC50 
was calculated using the “log[inhibitor] vs. the normalized response – variable 
slope” equation in GraphPad Prism 5.
CellTiter-Glo luminescent cell viability assay. The effect of UNC3866 and 
UNC4219 on cell viability was determined using a CellTiter-Glo ATP detection 
system (Promega #7573). Ten point, 1:3 dilution curves of compounds starting 
at 100 M final concentration were diluted to 5× final concentration in PBS 
(vehicle control) and then 5 l were added to 384-well white, clear bottom 
tissue culture plates (Corning #3707) with a Multimek automated liquid han-
dling device (Nanoscreen, Charleston, SC). Twenty microliters of low pas-
sage, subconfluent HEK293T/PC3 cells grown in Dulbecco’s Modified Eagle’s 
Medium without phenol red (GIBCO #31053) and supplemented with 10% 
Fetal Bovine Serum (GIBCO #26140) were immediately added at a density 
of 5,000 cells per well using a Multidrop 384 (Titertek). Cell plates were 
incubated for 48 h at 37 °C and 5% CO2 and then lysed with 25 microliters 
of CellTiter-Glo reagent. Luminescence was read on an Envision plate reader 
(Perkin Elmer) after 15 min at room temperature in dim light.
Cellular thermal shift assay (CETSA). A PC3 cell pellet consisting of 107 cells 
was re-suspended in 1,200 l of PBS complete with protease inhibitors. The 
suspension was subjected to 3 consecutive freeze-thaw cycles performed with 
liquid N2 in order to lyse the cells. Following the final freeze-thaw cycle, the 
suspension was centrifuged at 20,000g for 20 min at 4 °C. The supernatant was 
collected and the resulting pellet was discarded. The lysate was then divided 
into two tubes (600 l) each. The volume of each tube was brought up to 650 l 
with PBS + protease inhibitors. DMSO or 30 M UNC3866 was added to each 
tube. The tubes were incubated at RT for 30 min. The lysates were aliquoted 
into 12 thin-walled PCR tubes (50 l/tube). The tubes were incubated for 3 min 
at temperatures ranging from 37 °C to 73 °C in 3° increments in a Mastercycle 
nexus gradient qPCR machine. Tubes were then incubated at room tempera-
ture for 3 min followed by centrifugation at 20,000g for 20 min at 4 °C. The 
supernatant was collected. Ten microliters of 6× Laemmli buffer was added to 
each tube. The tubes were then heated to 95 °C for 3 min. Twenty microliters 
was then loaded into an SDS page gel and analyzed by western blotting.
CBX7 knockdown and quantitative PCR. PC3 cells were seeded at a density 
of 105 cells/well in a 6-well plate and allowed to adhere overnight. The media 
was then exchanged for 2 ml of media containing polybrene (8 g/ml) and pre- 
packaged shRNA (200,000 Transducing Units/well) targeting CBX7 (Mission 
CBX7, SHCLNV (Sigma) TRCN0000019144RNA) or Non-targeting control 
(Mission pLKO.1-puro Non-Target shRNA, SHC016V (Sigma)). After 20 h, the 
transduction mixture was exchanged with fresh media (GIBCO DMEM/F12 
(Ham) supplemented with l-glutamine and 15 mM HEPES) and allowed to incu-
bate for an additional 24 h. The media was then replaced with media containing 
2 g/ml of puromycin and allowed to incubate until selection was complete as 
evidence by the death of all control cells that were not transduced. RNA was 
extracted using the RNeasy Plus Mini Kit (Qiagen) and RNA was quantified on 
the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). The reverse 
transcription reaction was performed with 500 ng RNA and the Superscript III 
First Strand Synthesis Supermix (Invitrogen #1172-050) according to manu-
facturer instructions. The resulting cDNA was diluted 1:10, and 2 L was used 
for each PCR reaction. Quantitative PCR was performed using Roche FastStart 
Universal SYBR Green Master Mix (Rox) in a 384-well plate format on the ABI 
2900HT instrument. Oligo sequences are available upon request.
Phase contrast microscopy images. PC3 cells were seeded at 200 cells/well 
into 24-well plates (Costar #3524). Cells were allowed to adhere overnight. 
The media (DMEM supplemented with 10% FBS) was then exchanged with 
fresh media containing DMSO or 30 M UNC3866. On day 3, the media 
were exchanged with fresh media containing DMSO or 30 M UNC3866. 
At day 6, cells were fixed with ice-cold methanol for 30 s. and rehydrated with 
PBS. Samples were imaged using Volocity software and an Olympus IX81 
microscope equipped with an Orca ER digital camera.
Senescence-associated -Gal staining. PC3 cells were seeded in a 96-well plate 
at a density of 100–200 cells/well and allowed to adhere overnight. The media 
was then replaced with fresh media containing 30 M UNC3866 or DMSO. 
After 3 days, the media was removed and the cells were fixed and stained using 
the Senescence -Galactosidase Kit (#9860) from Cell Signaling Technology 
according to the manufacturer’s recommendations. Wells were imaged using 
bright-field microscopy with an Olympus IX81 microscope equipped with an 
Orca ER digital camera.
Protein expression and purification. Expression constructs. The chromo-
domains of CBX2 (residues 9–66 of NP_005180), CBX4 (residues 8–65 of 
NP_003646), CBX6 (residues 8–65 of NP_055107) and CBX8 (residues 8–61 
of NP_065700) were expressed with N-terminal His-tags in pET28 expres-
sion vectors. The chromodomain of CBX7 (residues 8–62 of NP_783640) 
was expressed with a C-terminal His-tag in a pET30 expression vector. The 
chromodomains of CDY1 (residues 1–101 of NP_733841), CDYL1b (residues 
1–78 of NP_004815) and CDYL2 (residues 1–75 of NP_689555) were expressed 
with N-terminal GST-tags in pGEX4T expression vector.
Protein expression and purification. All expression constructs were trans-
formed into Rosetta BL21(DE3)pLysS competent cells (Novagen, EMD 
Chemicals, San Diego, CA). Protein expression was induced by growing cells 
at 37 °C with shaking until the OD600 reached ~0.6–0.8 at which time the 
temperature was lowered to 18 °C and expression was induced by adding 
0.5 mM IPTG and continuing shaking overnight. Cells were harvested by 
centrifugation and pellets were stored at −80 °C.
His-tagged proteins were purified by re-suspending thawed cell pellets in 
30 ml of lysis buffer (50 mM sodium phosphate pH 7.2, 50 mM NaCl, 30 mM 
imidazole, 1× EDTA free protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN)) per liter of culture. Cells were lysed on ice by sonication 
with a Branson Digital 450 Sonifier (Branson Ultrasonics, Danbury, CT) 
at 40% amplitude for 12 cycles with each cycle consisting of a 20 s pulse 
followed by a 40 s rest. The cell lysate was clarified by centrifugation and loaded 
onto a HisTrap FF column (GE Healthcare, Piscataway, NJ) that had been 
preequilibrated with 10 column volumes of binding buffer (50 mM sodium 
phosphate, pH 7.2, 500 mM NaCl, 30mM imidazole) using an AKTA FPLC 
(GE Healthcare, Piscataway, NJ). The column was washed with 15 column 
volumes of binding buffer and protein was eluted in a linear gradient to 100% 
elution buffer (50 mM sodium phosphate, pH 7.2, 500 mM NaCl, 500 mM 
imidazole) over 20 column volumes. Peak fractions containing the desired 
protein were pooled and concentrated to 2 ml in Amicon Ultra-15 concentra-
tors 3,000 molecular weight cut-off (Merck Millipore, Carrigtwohill Co. Cork 
IRL). Concentrated protein was loaded onto a HiLoad 26/60 Superdex 75 prep 
grade column (GE Healthcare, Piscataway, NJ) that had been preequilibrated 
with 1.2 column volumes of sizing buffer (25 mM Tris, pH 7.5, 250 mM NaCl, 
2 mM DTT, 5% glycerol) using an ATKA Purifier (GE Healthcare, Piscataway, 
NJ). Protein was eluted isocratically in sizing buffer over 1.3 column volumes at 
a flow rate of 2 ml/min collecting 3-ml fractions. Peak fractions were analyzed 
for purity by SDS-PAGE and those containing pure protein were pooled and 
concentrated using Amicon Ultra-15 concentrators 3,000 molecular weight 
cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL).
GST-tagged proteins were purified by re-suspending thawed cell pellets in 
30 ml of lysis buffer (1× PBS, 5 mM DTT, 1× EDTA free protease inhibitor 
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Data collection/structure determination and refinement. Due to space restric-
tions, literature references to selected computer programs are provided in the 
Supplementary Information of refs. 4–16). Details on diffraction data and 
model refinement are given in Supplementary Table 15. Diffraction data for 
model refinement were collected at a copper rotating anode (CBX2, CBX7) 
or APS beamline 19ID (CBX4, CBX8; wavelength 0.979 Å). Diffraction inten-
sities were integrated with XDS58 and merged with AIMLESS59. Molecular 
replacement was performed with the program PHASER60. Geometry restraints 
for the modified lysyl residue as well as the 4-tert-butylbenzoyl protecting 
group were prepared with eLBOW/Mogul, restraints for selected peptide 
links with jLigand. Current crystallographic models underwent iterative re-
building, refinement and validation in COOT, REFMAC and MOLPROBITY, 
respectively. Favored regions of the respective model’s MOLPROBITY 
Ramachandran plot included at least 98% of the residues. Anisotropic dis-
placement parameters were analyzed on the PARVATI server. PDB_EXTRACT 
as well as PHENIX, IOTBX and CCP4 software were used to compile data for 
model deposition in the Protein Data Bank and for publication.
Specifically: CBX2. Coordinates from PDB entry 3H91 (ref. 3) were used 
for molecular replacement.
CBX4. The structure of an isomorphous crystal was solved by molecular 
replacement with CBX2 coordinates. ARP/WARP was used in “map improve-
ment” and “automated model building” modes. The model refinement was 
further refined against data from the current crystal.
CBX7. The structure was first solved in the lower-symmetry P41 setting by 
molecular replacement with coordinates from PDB entry 4MN3 (ref. 27). After 
merging of data in space group P41212, molecular replacement was performed 
with preliminarily refined CBX7 coordinates.
CBX8. The structure of an isomorphous crystal was solved by molecu-
lar replacement with CBX7 coordinates. ARP/WARP was used in “map 
improvement” and “automated model building” modes. The model was 
further refined against data from an additional crystal and, subsequently, 
the current crystal.
cocktail (Roche Diagnostics, Indianapolis, IN)) per liter of culture. Cells were 
lysed on ice by sonication as described for His-tagged proteins. Clarified cell 
lysate was loaded onto a GSTrap FF column (GE Healthcare, Piscataway, NJ) 
that had been pre-equilibrated with 10 column volumes of binding buffer 
(1x PBS, 5mM DTT) using a AKTA FPLC (GE Healthcare, Piscataway, NJ).  
The column was washed with 10 column volume s of binding buffer and pro-
tein was eluted in 100% elution buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 
10 mM reduced glutathione) over 10 column volumes. Peak fractions con-
taining the desired protein were pooled and concentrated to 2 ml in Amicon 
Ultra-15 concentrators, 10,000 molecular weight cut-off (Merck Millipore, 
Carrigtwohill Co. Cork IRL). Concentrated protein was loaded onto a HiLoad 
26/60 Superdex 200 prep grade column (GE Healthcare, Piscataway, NJ)  
that had been preequilibrated with 1.2 column volumes of sizing buffer  
(25 mM Tris, pH 7.5, 250 mM NaCl, 2 mM DTT, 5% glycerol) using an ATKA 
FPLC (GE Healthcare, Piscataway, NJ). Protein was eluted isocratically in 
sizing buffer over 1.3 column volumes at a flow rate of 2 ml/min collecting 
3-ml fractions. Peak fractions were analyzed for purity by SDS-PAGE and 
those containing pure protein were pooled and concentrated using Amicon 
Ultra-15 concentrators 10,000 molecular weight cut-off (Merck Millipore, 
Carrigtwohill Co. Cork IRL).
Affinity tag removal. The N-terminal affinity tag was removed from CBX2, 
CBX6, CDY1, CDYL1b and CDYL2 by thrombin cleavage according to man-
ufacturer’s recommendations (Novagen, EMD Chemicals, San Diego, CA). 
Briefly, purified protein was incubated with biotinylated thrombin at a final 
concentration of 1 unit thrombin per milligram tagged protein for 16 h at 4 °C.  
The cleavage reaction was then passed over either a HisTrap FF column  
(His-tagged proteins) or a GSTrap FF column (GST-tagged proteins) to remove 
any protein that still retained the tag. The column flow through was collected 
and incubated with streptavidin agarose to remove thrombin from the sample. 
Streptavidin agarose was removed from the sample by centrifugation and the 
protein was concentrated using Amico Ultra-15 concentrators, 3,000 molecular  
weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL). Protein was 
exchanged into a buffer containing 25 mM Tris, pH 7.5, 150 mM NaCl, 2 mM 
-mercaptoethanol before use in ITC.
X-ray crystallography. Preparation of proteins for crystallization. Expression 
and purification followed a previous description3. The coding DNA fragments 
of single chromodomains of CBX2 (residues 9–62), CBX4 (residues 8–65), 
CBX7 (residues 8–62) and CBX8 (residues 8–61) were subcloned into modified 
pET28-MHL or pET28a-Lic vectors to encode N-terminal His-tagged fusion 
proteins. Recombinant proteins were overexpressed in E. coli BL21 (DE3) 
Codon plus RIL cells (Stratagene) at 15 °C, purified by affinity chromatogra-
phy on Ni-nitrilotriacetate resin (Qiagen), and treated with TEV or thrombin 
protease to remove the tag. The proteins were further purified by gel filtration 
over a Superdex75 column (GE Healthcare, Piscataway, NJ). For crystallization, 
purified proteins were concentrated to 10 mg/ml in a buffer containing 20 mM 
Tris, pH 7.5, 150 mM NaCl and 1 mM DTT.
Crystallization. Purified protein was mixed with compound at a 1:2 molar 
ratio and crystallized using the sitting drop vapor diffusion method at 18–20 °C  
by mixing 0.5 L of the protein with 0.5 L of the reservoir solution. Reservoir 
solutions were 20% PEG 3350, 0.2 M KSCN for CBX2, 30% PEG 3350, 0.2 M  
NaCl, 0.1 M sodium cacodylate, pH 5.5 for CBX4, 20% PEG 3350, 0.2 M 
ammonium formate for CBX7, and 1.4 M sodium citrate, 0.1 M HEPES,  
pH 7.5, 5% glycerol for CBX8. Crystals were soaked in a cryoprotectant  
consisting of 85% reservoir solution and 15% glycerol, and flash-frozen in 
liquid nitrogen.
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In our original Article, we reported the discovery of a chemical probe for the CBX domains of Polycomb repressive complex 1 (PRC1). 
In subsequent studies undertaken in our laboratories by Kelsey Lamb (Center for Integrative Chemical Biology and Drug Discovery, 
Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel 
Hill, Chapel Hill, NC, USA), we have observed that our modular synthetic approach detailed in this article leads to epimerization at the 
alanine position. In the reported synthesis in the original paper, the amide coupling of tripeptide intermediate 13 to tripeptide interme-
diate 7 for the formation of final product UNC3866 (or for the formation of UNC4219, the amide coupling of tripeptide intermediate 
13 to tripeptide intermediate 10) resulted in approximately 40% epimerization at the alanine side chain by NMR. The linear approach 
outlined in the revised protocol in the Supplementary Note avoids this problem by utilizing a synthetic route in which each amide 
coupling is performed on the N-Boc-protected amino acid, a method known to diminish epimerization, as validated in our studies by 
NMR spectra. We note that UNC3866 was originally synthesized using the linear route, despite the modular synthesis reported in the 
original Supplementary Note, and therefore biological data reported for this compound were not affected. While UNC4219, UNC4007 
and UNC4195 were synthesized using the modular route, resynthesis of compounds by the linear route validated that all data obtained 
using these compounds were unaffected by alanine epimerization. Based on these observations, we provide an alternative synthetic route 
in this Addendum that avoids alanine epimerization. The protocols have been updated in the Supplementary Note to this Addendum.
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